Posts

Do Psychedelics Hold the Key to Explaining Near-Death Experiences?

Do Psychedelics Hold the Key to Explaining Near-Death Experiences?

New research into psychedelics shows it may help scientists better understand the phenomenon known as near-death experiences.
Is There a Case for Keeping Psychedelics Illegal? Ethics, Conservation, and Indigenous Rights

Is There a Case for Keeping Psychedelics Illegal? Ethics, Conservation, and Indigenous Rights

,
If decriminalization efforts strain natural plant and animal medicine populations, should psychedelics remain illegal?
Algernon to Become the First Company in the World to Study DMT for Stroke Patients

Algernon to Become the First Company in the World to Study DMT for Stroke Patients

Algernon Pharmaceuticals has received FDA approval to study DMT for use in stroke patients to help rebuild synaptic connections.
DMT-Focused Psychedelic Company Small Pharma Launches on TSX Venture Exchange

DMT-Focused Psychedelic Company Small Pharma Launches on TSX Venture Exchange

DMT-focused psychedelic therapy company Small Pharma is listing on the Canadian TSK Venture Exchange as it ramps up its offerings.
Psychedelic Business News Spotlight: May 7, 2021

Psychedelic Business News Spotlight: May 7, 2021

This week in psychedelic business news: LSD for pain, DMT and organ transplants, Champignon Brands is now Braxia Scientific Corp, and more.
GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
Small Pharma Clinical Trials to Study DMT for Treatment-Resistant Depression

Small Pharma Clinical Trials to Study DMT for Treatment-Resistant Depression

Small Pharma is going into clinical trials to look at DMT for depression relief. The UK company says it believes benefits will be immediate.
Algernon to Investigate DMT Microdose for Stroke Treatment

Algernon to Investigate DMT Microdose for Stroke Treatment

Algernon Pharmaceuticals is exploring the little-researched psychedelic substance DMT to see if it has potential in treating stroke patients.
Core One Labs and Ketamine Infusion Centers to Explore DMT Research for Anxiety and Depression

Core One Labs and Ketamine Infusion Centers to Explore DMT Therapy for Anxiety and Depression

Core One Labs is exploring DMT therapy for anxiety and depression in a partnership with Ketamine Infusion Centers.